



James C. Foster

Chairman, President & Chief Executive Officer

James C. Foster is Chairman of the Board, President and Chief Executive Officer of Charles River Laboratories, a leading provider of essential products and services that fully support the drug discovery and early-stage development process. Since beginning his career at Charles River in 1976, Mr. Foster has held a variety of senior level positions, culminating to being named President in 1991, Chief Executive Officer (CEO) in 1992, and Chairman in 2000.

As CEO, Mr. Foster has built Charles River from a niche research models and services business to a full service, early-stage drug research partner, expanding the Company's revenues from approximately \$160 million to more than \$2.25 billion. Since its IPO in June 2000, Charles River's stock price has appreciated at a compound annual growth rate of more than 10%.

Mr. Foster's entrepreneurial spirit and market knowledge have enabled him to expand the Company by skillfully adapting to industry trends and anticipating client needs. Under his leadership, Charles River has completed more than 40 acquisitions and plays an increasingly important role in the drug development process. This is evident in the fact that the Company worked on 85% of the drugs approved by the FDA in 2018.

In October 2002, he was named “Entrepreneur of the Year” by Forbes Magazine, noting his ability to dramatically increase profitability by moving the company in new directions through both acquisition and organic growth. He is a member of the Board of Trustees of the Institute of Contemporary Art in Boston. Mr. Foster is also a member of the Presidential Advisory Council for Berklee College of Music. He is a member of the Strategic Advisory Board for the Longwood Fund, and a member of the Board of The Esplanade Association. He is a guest lecturer at the Massachusetts Institute of Technology (MIT).

Mr. Foster holds a B.A. degree from Lake Forest College, an M.S. degree from MIT, and a J.D. degree from Boston University School of Law.



David R. Smith

Corporate Executive Vice President & Chief Financial Officer

David Smith joined Charles River with the acquisition of Argenta and BioFocus in April 2014. Following the acquisition, Mr. Smith assumed the role of Corporate Vice President, Charles River Early Discovery Services, and in October 2014, was promoted to Corporate Senior Vice President, Global Discovery Services. In August 2015, Mr. Smith was promoted to Corporate Executive Vice President and Chief Financial Officer. In this role, Mr. Smith leads the Company's global Finance organization and is responsible for overseeing Accounting, Tax, Treasury, Investor Relations, Internal Audit, Risk Management, and Procurement. He is a member of the Company's Executive Committee.

Prior to joining Charles River, Mr. Smith had been Chief Executive Officer of Galapagos Services, the contract research services division of Belgian biotech Galapagos NV, which included Argenta and BioFocus. He had held this position since August 2013. Previously, he was Chief Financial Officer of Cambridge University Hospitals from 2007 to 2013, and of Galapagos NV between 2006 and 2007, during which time he played a key role in several merger and acquisition projects to build the services division. From 1997 to 2005, Mr. Smith held Marketing Company Chief Financial Officer and R&D Finance roles at AstraZeneca in the United Kingdom, Sweden, Hungary, and the Netherlands, and worked as a Chartered Accountant with PricewaterhouseCoopers in the United Kingdom and Dubai between 1989 and 1997.

Mr. Smith received a B.Sc. Honours degree in Molecular Biophysics from the University of Leeds.



Birgit Girshick
Corporate Executive Vice President,
Discovery, Safety Assessment, Biologics Testing Solutions,
and Avian Vaccine Services

Birgit Girshick joined Charles River in 1989 and held positions of increasing responsibility in the Company's Research Models and Services (RMS) Germany and Avian Vaccine Services businesses. In 2010, Ms. Girshick was promoted to Corporate Vice President, Biologics Testing Solutions, followed by a promotion to Corporate Senior Vice President, Research Models and Biologics Testing Solutions in 2013. In 2016, Ms. Girshick assumed responsibility for the Global Discovery Services business. In 2018, Ms. Girshick was promoted to Corporate Executive Vice President overseeing the Discovery, Safety Assessment, Biologics Testing Solutions and Avian Vaccine Services business units. In this role, Ms. Girshick is responsible for leading these global businesses, which includes guiding their strategic direction, driving operational excellence and growth, maintaining client and partnership relationships, and integrating acquisitions. She is a member of the Company's Executive Committee.

Ms. Girshick holds a B.A. degree from Eastern Connecticut State University and an M.B.A. degree from the University of Rhode Island. She is also a graduate of the Advanced Management Program at the MIT Sloan School of Management.



Professor Julie Frearson, Ph.D.
Corporate Vice President, Strategic Alliances

Julie Frearson, Ph.D. joined Charles River in 2014 to lead Charles River's effort in developing and managing strategic venture fund and technology partnerships across the Company's business units. Dr. Frearson has substantial experience in early-stage drug discovery across multiple gene families and therapeutic areas, as a result of roles with The Babraham Institute (Cambridge, UK), Zeneca UK, BioFocus, and a faculty position in the Drug Discovery Unit of the University of Dundee, prior to joining Charles River. A strong advocate of early translational drug discovery from academic concepts, Dr. Frearson has served as Director for Scottish Universities Life Sciences Alliance (SULSA), the Medical Research Council (United Kingdom), and The Wellcome Trust Committees. Dr. Frearson is co-author of more than 60 peer-reviewed publications.

Dr. Frearson received a Ph.D. in Biochemistry from King's College London, University of London.



Ian Jester

Corporate Vice President, Microbial Solutions

Ian Jester joined Charles River in 1997 as an Account Manager, representing the Microbial Solutions, Research Models, and Biologics Testing Solutions (Biologics) business units in California. In his 22-year tenure at Charles River, Mr. Jester has successfully held roles of increasing responsibility within the commercial organization. In 2008, he assumed the role of Director of Sales for the Microbial Solutions and Biologics divisions, and in 2009, he transitioned to a dedicated role with the Microbial Solutions business as Executive Director of Global Sales. In 2016, Mr. Jester was promoted to Corporate Vice President, Global Sales for Microbial Solutions. In this role, he is responsible for leading the global commercial team, including Account Management, Field Operations, and Technical Product Specialists, by driving performance and profitability, increasing client satisfaction, and ensuring cross-functional strategic alignment for the organization.

Mr. Jester received his B.A. degree from the University of California, Los Angeles and his M.B.A. degree from the University of San Francisco.



Kerstin S. Dolph
Corporate Vice President,
Global Biologics Testing Solutions

Kerstin Dolph joined Charles River in 2001 in a Finance role for our Research Models and Services (RMS) business in Germany. She transitioned to the U.S. RMS business in 2009 and held Finance positions of increasing responsibility, and in 2015, she was promoted to Senior Finance Director for Global RMS. In 2017, Ms. Dolph was promoted to Corporate Vice President, North American RMS. In this role, she was responsible for leading the Company's North American RMS business, which included managing several consolidation and efficiency initiatives, along with global RMS technology enhancements.

In 2019, she transitioned into her current role as Corporate Vice President, Global Biologics Testing Solutions. In this role, Ms. Dolph is responsible for leading the Company's Biologics business, as well as managing its growth opportunities and the expansion of the business.

Ms. Dolph received her degree from the International Accountancy & Business School in Wuerzburg, Germany and was recognized by the Bavarian Government for outstanding performance.



Colin Dunn, Ph.D.
Corporate Senior Vice President,
Global Research Models & Services

Colin Dunn, Ph.D., joined Charles River in 2008 as Country Manager for the Company's Research Models and Service (RMS) businesses in the United Kingdom and as Executive Director for Veterinary and Professional Services in Europe. In 2011, Dr. Dunn was promoted to Corporate Vice President, Research Models & Services, Europe. In 2013, he was promoted to Corporate Senior Vice President and General Manager, Research Models & Services, Europe and Asia, and in 2016, assumed responsibility for the Company's global RMS operations. In this role, Dr. Dunn is responsible for leading the global RMS business, as well as identifying new growth opportunities and driving operating efficiency.

Dr. Dunn received a B.S. degree in Veterinary Medicine from the University of Glasgow and a Ph.D. in Virology from the Université Louis Pasteur (Strasbourg, France).



Todd Spencer

Corporate Vice President, Investor Relations

Todd Spencer joined Charles River Laboratories in 2006 as Manager, Investor Relations. Mr. Spencer progressed in the Investor Relations role through positions of increasing responsibility, and in June 2018, was promoted to Corporate Vice President, Investor Relations. In this role, Mr. Spencer manages the Company's relationship with the investment community, and is responsible for effectively communicating Charles River's business strategy and financial performance. Prior to joining Charles River, Mr. Spencer was Manager, Investor Relations, for Fisher Scientific, prior to its merger with Thermo Electron Corporation. Mr. Spencer began his career in Fisher Scientific's Corporate Development group, where he was primarily responsible for evaluating acquisition candidates and conducting competitive analysis.

Mr. Spencer holds a B.S. degree in Business Administration from the University of New Hampshire. He is also a member of the National Investor Relations Institute (NIRI) professional association.